ICS sensitivity of PRISE #1 and #2 genes in SYMBEXCO and independent RNA-sequencing dataset
| Gene | SYMBEXCO: ICS treatment → no ICS (8 weeks) | Independent RNA-seq dataset: no ICS → ICS treatment (8 weeks) | ||
| Log2 fold change | Nominal p-value | Log2 fold change | Nominal p-value | |
| CLC (PRISE #1) | 0.76 | <0.01* | −2.88 | 0.01* |
| LGALS12 (PRISE #1) | 0.52 | 0.01* | −1.52 | 0.01* |
| CD24 (PRISE #1) | 0.30 | 0.04* | NA | NA |
| ALOX15 (PRISE #1) | 0.42 | 0.04* | −1.17 | <0.01* |
| EMR4P (PRISE #1) | 0.22 | 0.13 | −0.63 | 0.16 |
| IL1RL1 (PRISE #1) | 0.15 | 0.36 | −1.32 | 0.03* |
| ALG3 (PRISE #2) | −0.02 | 0.85 | −0.49 | 0.02* |
| CCDC152 (PRISE #2) | −0.02 | 0.91 | 0.27 | 0.16 |
| SEPP1 (PRISE #2) | 0.01 | 0.96 | −0.22 | 0.08 |
ICS: inhaled corticosteroid. *: p<0.05.